Kibdelomycin is a bactericidal broad-spectrum aerobic antibacterial agent

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 6, 2015, Pages 3474-3481

  Singh, Sheo B ^a,c   Dayananth, Priya ^a   Balibar, Carl J ^a   Garlisi, Charles G ^a   Lu, Jun ^a   Kishii, Ryuta ^b   Takei, Masaya ^b   Fukuda, Yasumichi ^b,c   Ha, Sookhee ^a   Young, Katherine ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b KYORIN PHARMACEUTICAL CO LTD   (Japan)

^c SBS Pharma Consulting LLC ^*  (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CHLORAMPHENICOL; CIPROFLOXACIN; COUMARIN DERIVATIVE; ERYTHROMYCIN; IMIPENEM; KIBDELOMYCIN; LEVOFLOXACIN; LINEZOLID; NOVOBIOCIN; QUINOLONE DERIVATIVE; RIFAMPICIN; TETRACYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN; 2 PYRROLIDONE DERIVATIVE; PYRROLE DERIVATIVE;

ACINETOBACTER BAUMANNII; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL STRUCTURES; BACTERICIDAL ACTIVITY; CHEMICAL MODIFICATION; CONTROLLED STUDY; CROSS RESISTANCE; DRUG POTENCY; DRUG STRUCTURE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IC50; IN VITRO STUDY; MEMBRANE PERMEABILITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTER MEMBRANE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; ESCHERICHIA COLI; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PYRROLES; PYRROLIDINONES; STAPHYLOCOCCUS AUREUS;

EID: 84929587489     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00382-15     Document Type: Article

References (31)

1. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771. http://dx.doi.org/10.1001/jama.298.15.1763.
2. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12. http://dx.doi.org/10.1086/595011.
3. Singh SB, Barrett JF. 2006. Empirical antibacterial drug discovery- foundation in natural products. Biochem Pharmacol 71:1006-1015. http://dx.doi.org/10.1016/j.bcp.2005.12.016.
4. Walsh CT. 2003. Antibiotics: actions, origin, resistance. ASM Press, Washington, DC.
5. Wang J, Soisson SM, Young K, Shoop W, Kodali S, Galgoci A, Painter R, Parthasarathy G, Tang Y, Cummings R, Ha S, Dorso K, Motyl M, Jayasuriya H, Ondeyka J, Herath K, Zhang C, Hernandez L, Alloco J, Basilio Á, Tormo JR, Genilloud O, Vicente F, Pelaez F, Colwell L, Lee SH, Michael B, Felcetto T, Gill C, Silver LL, Hermes J, Bartizal K, Barrett J, Schmatz D, Becker JW, Cully D, Singh SB. 2006. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441:358-361. http://dx.doi.org/10.1038/nature04784.
6. Singh SB, Jayasuriya H, Ondeyka JG, Herath KB, Zhang C, Zink DL, Tsou NN, Ball RG, Basilio A, Genilloud O, Diez MT, Vicente F, Pelaez F, Young K, Wang J. 2006. Isolation, structure, and absolute stereochemistry of platensimycin, a broad spectrum antibiotic discovered using an antisense differential sensitivity strategy. J Am Chem Soc 128:11916-11920. http://dx.doi.org/10.1021/ja062232p.
7. Wang J, Kodali S, Lee SH, Galgoci A, Painter R, Dorso K, Racine F, Motyl M, Hernandez L, Tinney E, Colletti S, Herath K, Cummings R, Salazar O, Gonzalez I, Basilio A, Vicente F, Genilloud O, Pelaez F, Jayasuriya H, Young K, Cully D, Singh SB. 2007. Platencin is a dual FabF and FabH inhibitor with potent in vivo antibiotic properties. Proc Natl Acad Sci U S A 104:7612-7616. http://dx.doi.org/10.1073/pnas.0700746104.
8. Jayasuriya H, Herath KB, Zhang C, Zink DL, Basilio A, Genilloud O, Diez MT, Vicente F, Gonzalez I, Salazar O, Pelaez F, Cummings R, Ha S, Wang J, Singh SB. 2007. Isolation and structure of platencin: a novel FabH and FabF dual inhibitor with potent broad spectrum antibiotic activity produced by Streptomyces platensis MA7339. Angew Chem Int Ed Engl 46:4684-4688. http://dx.doi.org/10.1002/anie.200701058.
9. Phillips JW, Goetz MA, Smith SK, Zink DL, Polishook J, Onishi R, Salowe S, Wiltsie J, Allocco J, Sigmund J, Dorso K, Lee S, Skwish S, de la Cruz M, Martin J, Vicente F, Genilloud O, Lu J, Painter RE, Young K, Overbye K, Donald RG, Singh SB. 2011. Discovery of kibdelomycin, a potent new class of bacterial type II topoisomerase inhibitor by chemical-genetic profiling in Staphylococcus aureus. Chem Biol 18:955-965. http://dx.doi.org/10.1016/j.chembiol.2011.06.011.
10. Singh SB, Goetz MA, Smith SK, Zink DL, Polishook J, Onishi R, Salowe S, Wiltsie J, Allocco J, Sigmund J, Dorso K, de la Cruz M, Martin J, Vicente F, Genilloud O, Donald RG, Phillips JW. 2012. Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities. Bioorg Med Chem Lett 22:7127-7130. http://dx.doi.org/10.1016/j.bmcl.2012.09.071.
11. Miesel L, Hecht DW, Osmolski JR, Gerding D, Flattery A, Li F, Lan J, Lipari P, Polishook JD, Liang L, Liu J, Olsen DB, Singh SB. 2014. Kibdelomycin is a potent and selective agent against toxigenic Clostridium difficile. Antimicrob Agents Chemother 58:2387-2392. http://dx.doi.org/10.1128/AAC.00021-14.
12. Lu J, Patel S, Sharma N, Soisson SM, Kishii R, Takei M, Fukuda Y, Lumb KJ, Singh SB. 2014. Structures of kibdelomycin bound to Staphylococcus aureus GyrB and ParE showed a novel U-shaped binding mode. ACS Chem Biol 9:2023-2031. http://dx.doi.org/10.1021/cb5001197.
13. Morita Y, Kodama K, Shiota S, Mine T, Kataoka A, Mizushima T, Tsuchiya T. 1998. NorM, a putative multidrug efflux protein, of Vibrio parahaemolyticus and its homolog in Escherichia coli. Antimicrob Agents Chemother 42:1778-1782.
14. Fukuda H, Hori S, Hiramatsu K. 1998. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus. Antimicrob Agents Chemother 42:1917-1922.
15. Fukuda H. 2000. Genetic study of the mechanisms of action of fluoro-quinolones in Streptococcus pneumoniae. Jpn J Chemother 48:243-250.
16. Fukuda H, Hosaka M, Hirai K, Iyobe S. 1990. New norfloxacin resistance gene in Pseudomonas aeruginosa PAO. Antimicrob Agents Chemother 34:1757-1761. http://dx.doi.org/10.1128/AAC.34.9.1757.
17. Chow JW, Satishchandran V, Snyder TA, Harvey CM, Friedland IR, Dinubile MJ. 2005. In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART). Surg Infect (Larchmt) 6:439-448. http://dx.doi.org/10.1089/sur.2005.6.439.
18. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. NCCLS document M26-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
19. Jett BD, Hatter KL, Huycke MM, Gilmore MS. 1997. Simplified agar plate method for quantifying viable bacteria. Biotechniques 23:648-650.
20. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci USA97:6640-6645. http://dx.doi.org/10.1073/pnas.120163297.
21. Balibar CJ, Hollis-Symynkywicz MF, Tao J. 2011. Pantethine rescues phosphopantothenoylcysteine synthetase and phosphopantothenoylcysteine decarboxylase deficiency in Escherichia coli but not in Pseudomonas aeruginosa. J Bacteriol 193:3304-3312. http://dx.doi.org/10.1128/JB.00334-11.
22. Hoang TT, Karkhoff-Schweizer RR, Kutchma AJ, Schweizer HP. 1998. A broad-host-range Flp-FRT recombination system for site-specific excision of chromosomally-located DNA sequences: application for isolation of unmarked Pseudomonas aeruginosa mutants. Gene 212:77-86. http://dx.doi.org/10.1016/S0378-1119(98)00130-9.
23. Sawitzke JA, Austin S. 2000. Suppression of chromosome segregation defects of Escherichia coli muk mutants by mutations in topoisomerase I. Proc Natl Acad Sci U S A 97:1671-1676. http://dx.doi.org/10.1073/pnas.030528397.
24. López CM, Rholl DA, Trunck LA, Schweizer HP. 2009. Versatile dual-technology system for markerless allele replacement in Burkholderia pseudomallei. Appl Environ Microbiol 75:6496-6503. http://dx.doi.org/10.1128/AEM.01669-09.
25. Singh SB, Kaelin DE, Wu J, Miesel L, Tan CM, Meinke PT, Olsen D, Lagrutta A, Bradley P, Lu J, Patel S, Rickert KW, Smith RF, Soisson S, Wei C, Fukuda H, Kishii R, Takei M, Fukuda Y. 2014. Oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad spectrum antibacterial agents. ACS Med Chem Lett 5:609-614. http://dx.doi.org/10.1021/ml500069w.
26. Singh SB, Kaelin DE, Wu J, Miesel L, Tan CM, Black T, Nargund R, Meinke PT, Olsen DB, Lagrutta A, Lu J, Patel S, Rickert KW, Smith RF, Soisson S, Sherer E, Joyce LO, Wei C, Peng X, Wang X, Fukuda H, Kishii R, Takei M, Takano H, Shibasaki M, Yajima M, Nishimura A, Shibata T, Fukuda Y. 24 March 2015. Tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of left-hand-side moiety (part-2). Bioorg Med Chem Lett http://dx.doi.org/10.1016/j.bmcl.2015.03.044.
27. Zimmermann W. 1979. Penetration through the Gram-negative cell wall: a co-determinant of the efficacy of beta-lactam antibiotics. Int J Clin Pharmacol Biopharm 17:131-134.
28. Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T, Henry R, Crane B, St Michael F, Cox AD, Adler B, Nation RL, Li J, Boyce JD. 2010. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 54:4971-4977. http://dx.doi.org/10.1128/AAC.00834-10.
29. Young K, Silver LL. 1991. Leakage of periplasmic enzymes from envA1 strains of Escherichia coli. J Bacteriol 173:3609-3614.
30. Kodali S, Galgoci A, Young K, Painter R, Silver LL, Herath KB, Singh SB, Cully D, Barrett JF, Schmatz D, Wang J. 2005. Determination of selectivity and efficacy of fatty acid synthesis inhibitors. J Biol Chem 280: 1669-1677. http://dx.doi.org/10.1074/jbc.M406848200.
31. Robertson GT, Doyle TB, Du Q, Duncan L, Mdluli KE, Lynch AS. 2007. A novel indole compound that inhibits Pseudomonas aeruginosa growth by targeting MreB is a substrate for MexAB-OprM. J Bacteriol 189:6870-6881. http://dx.doi.org/10.1128/JB.00805-07.